

HR for Mortality from Cancer For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCANCER
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1485

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1485	117	1368	92.12

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1682.575	1672.672
AIC	1682.575	1674.672
SBC	1682.575	1677.434

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	9.9031	1	0.0016
Score	9.5211	1	0.0020
Wald	9.5788	1	0.0020

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
logtxb	1	0.38602	0.12472	9.5788	0.0020	1.471

HR for Mortality from Cancer For Log UTXB by ASA Group**The PHREG Procedure**

Aspirin Use=No Aspirin Use

Hazard Ratios for logtxb			
Description	Point Estimate	95% Wald Confidence Limits	
logtxb Unit=1	1.471	1.152	1.879

HR for Mortality from Cancer For Log UTXB by ASA Group

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCANCER
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1087

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1087	113	974	89.60

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1534.141	1528.957
AIC	1534.141	1530.957
SBC	1534.141	1533.684

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	5.1845	1	0.0228
Score	5.5966	1	0.0180
Wald	5.6001	1	0.0180

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
logtxb	1	0.32846	0.13880	5.6001	0.0180	1.389

HR for Mortality from Cancer For Log UTXB by ASA Group**The PHREG Procedure**

Aspirin Use=Aspirin Use

Hazard Ratios for logtxb			
Description	Point Estimate	95% Wald Confidence Limits	
logtxb Unit=1	1.389	1.058	1.823

The PHREG Procedure

Model Information	
Data Set	WORK.SURVIVALCANCER
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	3044
Number of Observations Used	2572

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
2572	230	2342	91.06

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	3538.388	3519.326
AIC	3538.388	3521.326
SBC	3538.388	3524.765

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	19.0614	1	<.0001
Score	21.2919	1	<.0001
Wald	20.5997	1	<.0001

The PHREG Procedure

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	20.5997	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.63104	0.13904	20.5997	<.0001	1.880	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	1.880	1.431	2.468

The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCANCER
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1485

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1485	117	1368	92.12

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1682.575	1664.828
AIC	1682.575	1666.828
SBC	1682.575	1669.590

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	17.7472	1	<.0001
Score	20.4154	1	<.0001
Wald	19.2805	1	<.0001

The PHREG Procedure

Aspirin Use=No Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	19.2805	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.83131	0.18932	19.2805	<.0001	2.296	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	2.296	1.584	3.328

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVALCANCER
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1087

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1087	113	974	89.60

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	1534.141	1530.440
AIC	1534.141	1532.440
SBC	1534.141	1535.168

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	3.7008	1	0.0544
Score	3.9887	1	0.0458
Wald	3.9420	1	0.0471

The PHREG Procedure

Aspirin Use=Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	3.9420	0.0471

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.41153	0.20727	3.9420	0.0471	1.509	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	1.509	1.005	2.265